TL;DR
- What it is: PE-22-28 is a 7-amino-acid peptide derived from the stathmin (STMN1) protein, designed as a TREK-1 channel blocker with rapid-onset antidepressant and neuroprotective effects.
- Mechanism: Selectively inhibits TREK-1 (KCNK2) two-pore potassium channel, increasing serotonergic and noradrenergic neuron firing. Cuts through the SSRI lag time.
- Who it’s for: Treatment-resistant depression, post-TBI cognitive recovery, post-stroke rehabilitation under medical supervision.
- Differentiator: Acts within 24–72 hours — far faster than SSRIs which take 4–6 weeks. Mechanism is electrophysiological, not monoamine-flooding.
- Natural Plus angle: Acute use, not chronic. Pair with foundational cognitive infrastructure (UMP, DHA) so the firing improvement has membrane to work on.
The standard SSRI script is broken. You wait six weeks, half of patients respond modestly, and the other half end up worse — emotionally blunted, sexually dysfunctional, gaining weight. Meanwhile, French researchers identified a 7-amino-acid peptide derived from the stathmin protein that produces antidepressant effects in 72 hours, without the monoamine flood that drives most SSRI side effects. PE-22-28 is one of the most interesting peptides in research-only territory right now, and the mechanism is unique enough that the Enhanced Man should know about it.
Deep Biochemistry: How a Tiny Peptide Cuts Through Depression
PE-22-28 is a 7-amino-acid sequence: Tyr-Gln-Lys-Pro-Pro-Lys-Pro-NH2 (some sources cite slightly different sequences depending on the publication; the Heurteaux et al. work is the foundational reference). It’s derived from a region of the stathmin protein and was specifically engineered to inhibit the TREK-1 (KCNK2) two-pore-domain potassium channel.
TREK-1 is unusual. It’s a “leak” potassium channel that hyperpolarizes neurons — making them less likely to fire. In dorsal raphe serotonergic neurons and locus coeruleus noradrenergic neurons, high TREK-1 activity dampens output of monoamines into the cortex. Animal studies show TREK-1 knockout mice are constitutively resistant to depression-like behavior in forced swim and tail suspension paradigms. Blocking TREK-1 pharmacologically replicates this effect.
PE-22-28 binds with high specificity to TREK-1 (vs other K2P channels) and crosses the blood-brain barrier with reasonable efficiency for a peptide. The selectivity matters — drugs that hit multiple K2P channels would have unwanted cardiovascular effects. PE-22-28’s narrow target window is what makes it pharmacologically clean in animal models.
Downstream, increased firing of serotonergic and noradrenergic neurons increases monoamine availability in the cortex without raising synaptic concentrations through reuptake inhibition. That distinction matters — SSRIs drive emotional blunting in part because they push monoamines above baseline tonically. TREK-1 blockade restores phasic firing patterns, which seems to map better onto the actual neural code.
Half-life in plasma is short (likely under 30 minutes for an unmodified 7-mer peptide), but receptor occupancy and downstream effects persist far longer.
Tony Huge Laws of Biochemistry Physics: Law 4 — Self-Regulating Systems
Per the tony huge Laws of Biochemistry Physics, Law 4 (Self-Regulating Systems) is critical here. The depressed brain has hijacked itself into a low-firing equilibrium. SSRIs try to push past the homeostatic setpoint by flooding the synapse — and the system fights back via receptor downregulation, blunting, and the well-known “SSRI plateau.” PE-22-28 instead removes a brake on the firing system itself, allowing endogenous regulation to function. You’re not overriding homeostasis — you’re restoring the system’s ability to self-regulate at higher set point.
This is a different kind of intervention than chronic monoamine elevation, and it explains why animals don’t show the usual receptor downregulation patterns after PE-22-28. Working with the body’s regulatory architecture rather than against it is exactly what Law 4 demands.
Natural Plus Protocol
Important caveat: PE-22-28 is research-only. It is not approved for clinical use anywhere. Anyone using it should be doing so under physician supervision and self-experimentation framework. The discussion here is mechanistic and educational.
Dosing (research literature): Animal studies use 1–10 mg/kg subcutaneous. Human-equivalent extrapolation places this in the low milligram range, but no human dosing has been formally published. Underground reports suggest 250–1000 mcg subcutaneous in single or every-other-day administration.
Cycling: Acute use only — 2–4 weeks maximum, then off. The TREK-1 system is best targeted as an acute intervention rather than chronically suppressed.
Timing: Morning. The firing-increase effect is mild but should not be dosed late.
What to monitor: Mood, sleep, blood pressure (TREK-1 has cardiovascular roles too — watch for changes), and cognitive function. If anxiety increases, discontinue.
Stacking Recommendations
Per Law 5, PE-22-28 stacks with infrastructure-building compounds because the peptide increases firing while the stack provides the substrate for what those firing neurons do downstream.
| Stack Compound | Pathway | Why It Synergizes |
|---|---|---|
| Uridine + DHA + Choline | Synaptic membrane | Increased firing means increased synaptic remodeling demand. Mr. Happy Stack supplies materials. |
| Lion’s Mane | NGF/BDNF | Promotes new dendrite growth; PE-22-28 ensures those dendrites get used. |
| Selank | GABAergic anxiolytic | If TREK-1 blockade produces transient anxiety, Selank balances without sedating. |
| Cerebrolysin | Multi-target neuropeptide complex | Different mechanism, same goal — cognitive recovery from injury or chronic depression. |
Target Audience
Treatment-resistant depression patients (under physician supervision), post-TBI biohackers seeking accelerated cognitive recovery, post-stroke rehabilitation cases, men coming out of severe burnout, and biohackers researching novel antidepressant mechanisms. Not for: anyone with seizure disorder, untreated cardiac arrhythmia, or anyone who can simply use first-line treatments effectively.
Timeline / Results Table
| Timeframe | What to Expect |
|---|---|
| 24–72 hours | Mood lift onset in animal models. Anecdotal human reports follow similar timeline. Clearer thinking, less emotional flatness. |
| Week 1 | Sustained improvement in volition. Easier to initiate complex tasks. |
| Week 2 | Plateau effect for most users. Begin tapering plan. |
| Week 4+ | Discontinue. Acute use only. Re-evaluate after a 3-month washout if needed. |
Interesting Perspectives
The most fascinating aspect of PE-22-28 is what it implies about the entire psychiatric pharmacology paradigm. Eighty years of research has assumed depression is fundamentally a monoamine availability problem. The TREK-1 work suggests the actual problem may be a firing-rate problem — the same neurons fire less, regardless of how much serotonin is at the synapse. This is more consistent with the clinical observation that ketamine works in hours (it modulates electrophysiology directly) while SSRIs take weeks (they require receptor remodeling).
The contrarian tony huge take: psychiatry sells emotional blunting as a feature. SSRIs work in part because they take the edges off — both the painful edges and the joyful edges. PE-22-28 doesn’t do that, because the mechanism is fundamentally different. The Enhanced Man does not accept “feeling less” as the price of “feeling better.” Real intervention should restore full dynamic range.
An emerging research angle: TREK-1 is also implicated in neuropathic pain, ischemic stroke neuroprotection, and migraine pathology. PE-22-28’s pleiotropic effects may extend well beyond depression, with active research programs in stroke recovery in particular. Don’t be surprised if the first formal clinical use is for post-stroke cognitive deficit rather than primary depression.
Real-world pattern from the underground: men with treatment-resistant depression who have failed three or four SSRI/SNRI trials report rapid response to short PE-22-28 cycles. The pattern is consistent — fast onset, no emotional blunting, no sexual dysfunction. The downside is access (research-only) and short evidence base in humans.
References
References
- Heurteaux C et al. “Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype.” Nature Neuroscience, 2006. DOI
- Borsotto M et al. “Targeting two-pore domain K+ channels TREK-1 and TASK-3 for the treatment of depression.” British Journal of Pharmacology, 2015.
- Djillani A et al. “Shortened Spadin analogs display better TREK-1 inhibition, in-vivo stability and antidepressant activity.” Frontiers in Pharmacology, 2017.
- Veyssiere J et al. “PE-22-28, a novel antidepressant peptide active by intranasal administration.” Frontiers in Pharmacology, 2015.
- Mazella J et al. “Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design.” PLoS Biology, 2010.
- Devader C et al. “Implication of TREK-1 channel in cognitive disorders associated with hippocampal stress.” Journal of Affective Disorders, 2017.
Frequently Asked Questions
PE-22-28 sits at the cutting edge of the cognitive recovery and mood optimization protocols. See the cerebrolysin brain repair protocol for an alternative cognitive recovery peptide and Selank for anxiety regulation. For the structural foundation that supports any of these acute interventions, see the uridine monophosphate protocol.
Bottom line: PE-22-28 is a targeted, electrophysiology-based intervention that rapidly cuts through depression and may accelerate post-injury cognitive recovery. It’s research-only, the human evidence is sparse, and the Enhanced Man uses it as a short, deliberate intervention — not a chronic substitute for the foundational work of sleep, nutrition, and resistance training.